India, Sept. 7 -- Roivant (ROIV), a commercial-stage biopharmaceutical company, and its subsidiary, Pulmovant, announced that results from the Phase 2 PHocus study of Mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 on Tuesday, September 8, 2026.
Pulmonary hypertension (PH) is a chronic, progressive disorder marked by elevated blood pressure in the arteries that carry blood from the heart to the lungs.
Mosliciguat and Phase 2 PHocus Trial Details
Pulmovant's first investigational candidate, Mosliciguat, is a potential first-in-class once-daily inhaled sGC activator with a mechanism of action design...